Compare OPRX & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | DERM |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.5M | 135.3M |
| IPO Year | 2008 | 2021 |
| Metric | OPRX | DERM |
|---|---|---|
| Price | $7.17 | $5.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $16.67 | $12.67 |
| AVG Volume (30 Days) | ★ 516.7K | 331.7K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | 34.72 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $109,429,000.00 | $61,858,000.00 |
| Revenue This Year | $3.88 | $47.42 |
| Revenue Next Year | $8.49 | $55.93 |
| P/E Ratio | $26.56 | ★ N/A |
| Revenue Growth | ★ 18.78 | 10.20 |
| 52 Week Low | $5.54 | $4.31 |
| 52 Week High | $22.25 | $9.56 |
| Indicator | OPRX | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 38.85 |
| Support Level | $7.13 | $4.31 |
| Resistance Level | $7.34 | $8.12 |
| Average True Range (ATR) | 0.46 | 0.31 |
| MACD | 0.16 | 0.13 |
| Stochastic Oscillator | 88.37 | 68.07 |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.